Second Line Breast Cancer Trial

NCT00635713 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

588

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Anastrozole
DRUG: Fulvestrant

Sponsor

AstraZeneca